Cardinal Drops Eisai; Wholesaler Still Confident In Fee-For-Service Model
Executive Summary
Eisai is the first pharmaceutical company to be dropped by Cardinal after failing to accept new terms of payment for the wholesaler
You may also be interested in...
Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal
Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19
Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal
Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19
Cardinal Plans Generic Cardiolite, Other Moves To Expand Generic Presence
Cardinal Health expects to market its own generic version of Bristol-Myers Squibb's cardiac imaging agent Cardiolite (technetium Tc99m sestamibi) as part of a plan to expand its role in the generic sector